More stories
Psychedelic Bulletin #146: Numinus Drops Lab, Consolidates Clinics; Study Suggests DMT Safe and Effective...
This Issue: and lots more… Last week, Vancouver-based Numinus Wellness announced that it would make a number of changes that represent a broader “focus...
FILAMENT HEALTH CORP. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT UNIT OFFERING LED BY NEGEV CAPITAL
VANCOUVER, BC, Sept. 29, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:7QS) (“Filament” or the “Company“), a clinical-stage natural psychedelic drug...
So, You’ve Become a Psychedelic-Informed Practitioner. Now what?
The mental health landscape is undergoing a sea change, in part, due to increased recognition of psychedelic-assisted therapy as a paradigm shift in the...
Canadian Veteran Receives Approval for APEX’s Psilocybin Therapy Through Health Canada’s Special Access Program
Veteran to receive APEX-90 macrodose psilocybin drug product in combination with assisted psychotherapy consistent with SUMMIT-90 clinical trial protocol. VANCOUVER, BC, Sept. 27, 2023...
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™...
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward unlocking the potential of ketamine for unmet medical needs...
PT445 – The Drug War, Harm Reduction, and the Middle Ground Between Liberty and...
In this episode, Joe interviews Ethan Nadelmann: author, speaker, Founder and former Executive Director of Drug Policy Alliance, host of the PSYCHOACTIVE podcast, and...
Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020
Single and multiple oral doses of GM-1020, a novel non-competitive NMDA channel blocker, were well-tolerated with no serious or severe adverse events observed and...
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients...
Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not...
Numinus Wellness Inc. Announces At-The-Market Offering Equity Program
VANCOUVER, BC, Sept. 25, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), is pleased to announce that it...
Introduction to Psychedelic Therapy and Career Pathways
Dive deep with David Drapkin, LCSW as he explores the nuances of the budding world of psychedelic therapy.
The post Introduction to Psychedelic Therapy and...
A Vital Journey: Blue Osa, Costa Rica
Our Setting Blue Osa is a gem set in the pristine jungle in the Southern Osa Peninsula, one of the earth’s most vibrant natural environments. There...
PT444 – A Glimpse Into the Psychedelic Neuroscience Landscape
In this special episode, Melanie Pincus, Ph.D. and Manesh Girn, Ph.D., who joined David in episode 403 to discuss the launch of their new...
